GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

NCT00521014 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: filgrastim
BIOLOGICAL: rituximab
BIOLOGICAL: sargramostim
DRUG: carmustine
DRUG: cytarabine
DRUG: etoposide
DRUG: melphalan
PROCEDURE: autologous hematopoietic stem cell transplantation

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]